ConcertAI Unveils AI-Powered Precision Suite for Oncology

ConcertAI has launched its new Precision Suite, an AI-powered solution designed to enhance oncology insights and actions for healthcare and life sciences, announced in a press release. The suite leverages ConcertAI's CARAai platform and integrated Oncology Data to provide rapid, persona-tailored insights, optimizing clinical trials and improving patient outcomes.

The Precision Suite includes applications such as Precision Explorer, Precision Trials, and Precision GTM, each tailored to specific use cases in the healthcare ecosystem. Precision Explorer aids in uncovering actionable insights for health economics and outcomes research, while Precision Trials focuses on improving clinical trial operations. Precision GTM enhances commercialization strategies for oncology therapies by unifying diverse data types.

ConcertAI's Precision360 serves as the backbone of the suite, integrating various data sources to create a real-world data dataset. This integration allows for real-time access to actionable insights, significantly reducing delays in oncology research and decision-making. The suite is set to be available starting June 30, 2025, with Precision GTM following by July 31, 2025.